Abstract
A 71-year-old female patient with B-cell depletion due to treatment with an anti-CD20 monoclonal antibody was admitted for worsening COVID-19. Overall, she had persistent viral shedding, worsening respiratory failure, and progressive pneumonia that did not improve despite dexamethasone and antibiotic therapy. After administration of bamlanivimab, a monoclonal antibody with high affinity for the receptor-binding domain of the SARS-CoV-2 spike protein, inflammatory markers rapidly decreased, SARS-CoV2 RT-PCR became negative, and the patient improved clinically and radiologically. In conclusion, we demonstrated successful treatment of prolonged COVID-19 in a patient with severe B-cell aplasia with a virus-neutralizing monoclonal antibody.
【저자키워드】 COVID-19, immunodeficiency, monoclonal antibodies, B-Cell aplasia, 【초록키워드】 Dexamethasone, Treatment, SARS-CoV2, Pneumonia, monoclonal antibody, viral shedding, RT-PCR, Spike protein, female, Patient, Inflammatory marker, anti-CD20, B-cell, administration, Antibiotic therapy, worsening, high affinity, worsening respiratory failure, IMPROVE, the patient, clinically, demonstrated, the receptor-binding domain, virus-neutralizing, the SARS-CoV-2, 【제목키워드】 Treatment, bamlanivimab, Case report, Patient, anti-CD20, monoclonal,